secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2024-05-06T23:59:59+00:00
Accession:  0001728117-24-000052
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 1.02, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio enters global collaboration with Chiesi for seralutinib; receives $160M upfront
--------------------------------------------------------------------------------

- Receives $160M development reimbursement; eligible for up to $146M regulatory and $180M sales milestones.
- Gossamer leads US commercialization for PAH/PH-ILD with 50/50 profit split; Chiesi obtains ex-US rights with tiered royalties.
- Companies plan to initiate Phase 3 registrational study of seralutinib in PH-ILD in mid-2025.
- Existing MidCap credit facility terminated and repaid in full upon deal closing.
- Chiesi receives equity option to purchase up to 9.9% of Gossamer at 107.5% of VWAP, min $1.63/share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000052/0001728117-24-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000052/goss-20240503.htm
  HTML page:      https://secwatch.observer/filing/0001728117-24-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer